BioMarin Pharmaceutical Inc.
BMRN
$58.14
$0.290.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 109.43% | 513.22% | 162.72% | 91.25% | 74.35% |
| Total Depreciation and Amortization | -19.31% | -12.11% | -26.00% | 4.11% | 3.52% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 57.11% | 55.41% | 93.27% | 1.45% | -44.46% |
| Change in Net Operating Assets | 14.16% | 14.38% | -2.15% | -6.73% | 51.35% |
| Cash from Operations | 271.28% | 575.42% | 63.28% | 69.51% | 163.53% |
| Capital Expenditure | 35.76% | 32.46% | 15.05% | 1.19% | -6.74% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -196.65% | 366.14% | 109.58% | 118.74% | 313.61% |
| Cash from Investing | -98.36% | 217.61% | 64.72% | 206.40% | 52.57% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -30,370.76% | 97.10% | -- |
| Issuance of Common Stock | -- | -46.90% | 10.15% | 1.37% | -66.00% |
| Repurchase of Common Stock | 22.36% | -25.23% | -30.31% | -2.14% | 2.87% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -108.89% | -37.57% | -- | 99.56% |
| Cash from Financing | 9.38% | -73.63% | -63,240.74% | 5.43% | -5.03% |
| Foreign Exchange rate Adjustments | -173.48% | 168.66% | -246.96% | 19.91% | 741.48% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,403.17% | 982.87% | -425.93% | 96.97% | 94.37% |